Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials

医学 荟萃分析 随机对照试验 内科学 不利影响 置信区间 系统回顾 子群分析 癌症 肿瘤科 梅德林 政治学 法学
作者
Hang Yuan,Dandan Duan,Yajun Zhang
出处
期刊:Clinics and Research in Hepatology and Gastroenterology [Elsevier]
卷期号:46 (10): 102031-102031 被引量:2
标识
DOI:10.1016/j.clinre.2022.102031
摘要

Immune checkpoint inhibitors (ICIs) have been recognized as an effective treatment for advanced gastric or gastroesophageal junction cancer (AG/GEJC). However, the safety of ICIs in patients has not been established. We aimed to systematically assess the risk of all common treatment-related adverse events (TRAEs) in immunotherapy of AG/GEJC.A systematic search of randomized controlled trials (RCTs) published until May 2022 was performed using PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. And a meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.A total of nine RCTs, including 2918 patients, met the eligibility criteria. The pooled overall incidences of all grade TRAEs, grade 3 or higher TRAEs and treatment-related death were 54.5% (95% confidence interval [CI]: 48.7%-60.2%, I2=75.55%), 12.8% (95% CI: 10.2%-15.7%, I2=51.61%) and 0.11% (95% CI: 0.00%-0.51%, I2=1.63%). Subgroup analyses showed that CTLA-4 inhibitors had a higher risk of any type of TRAEs, when compared with PD-1 and PD-L1 inhibitors. Meta-regression showed significant correlation between all grade TRAEs and proportion of female. Fatigue and diarrhoea were involved in common TRAEs.Our study provides a comprehensive overview of ICIs-associated AEs in AG/GEJC. Immunotherapy did not have a significantly increased risk experiencing any type of TRAEs, and ICIs had a more manageable safety profile than chemotherapy. These findings provide important guidance to clinicians in counseling and management of patients with AG/GEJC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
didida完成签到,获得积分10
2秒前
Ash发布了新的文献求助10
3秒前
4秒前
Zfy发布了新的文献求助10
5秒前
look完成签到,获得积分10
6秒前
迷人素完成签到 ,获得积分10
6秒前
刘佳婷发布了新的文献求助10
7秒前
liian7应助SICHEN采纳,获得20
8秒前
从容芷容应助SICHEN采纳,获得20
8秒前
zho关闭了zho文献求助
10秒前
大个应助露似珍珠月似弓采纳,获得10
11秒前
儒雅的雁山完成签到 ,获得积分10
12秒前
PhDshi应助机器猫采纳,获得10
13秒前
Ash完成签到,获得积分20
14秒前
星辰大海应助科研进化中采纳,获得10
21秒前
21秒前
好纠结完成签到,获得积分10
21秒前
orixero应助酷酷的友灵采纳,获得10
22秒前
可罗雀完成签到,获得积分10
22秒前
APPLE完成签到 ,获得积分10
22秒前
何江双完成签到,获得积分20
23秒前
低調的八哒鸟完成签到,获得积分10
25秒前
26秒前
liian7应助研友_ngqjz8采纳,获得30
27秒前
丘比特应助刘佳婷采纳,获得10
27秒前
田様应助科研通管家采纳,获得10
27秒前
顾矜应助科研通管家采纳,获得10
27秒前
小马甲应助科研通管家采纳,获得10
27秒前
JamesPei应助科研通管家采纳,获得10
27秒前
我是老大应助科研通管家采纳,获得10
27秒前
852应助科研通管家采纳,获得10
27秒前
田様应助科研通管家采纳,获得10
28秒前
慕青应助科研通管家采纳,获得30
28秒前
丘比特应助科研通管家采纳,获得30
28秒前
今后应助科研通管家采纳,获得10
28秒前
852应助科研通管家采纳,获得30
28秒前
Akim应助源源采纳,获得10
29秒前
30秒前
小马发布了新的文献求助20
32秒前
32秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3161007
求助须知:如何正确求助?哪些是违规求助? 2812311
关于积分的说明 7895133
捐赠科研通 2471181
什么是DOI,文献DOI怎么找? 1315908
科研通“疑难数据库(出版商)”最低求助积分说明 631071
版权声明 602086